Industry-Sponsored COVID-19 Drug and Vaccine National Clinical Trials (NCT) Found in www.clinicaltrials.gov Using Search Terms: COVID-19; Pediatric; Industry-sponsored.
Industry-Sponsored COVID-19 Drug and Vaccine National Clinical Trials (NCT) Found in www.clinicaltrials.gov Using Search Terms: COVID-19; Pediatric; Industry-sponsored.
| # | NCT No. | Abbreviated Study Design | Age (Number; Centers*) | Status |
|---|---|---|---|---|
| 1 | 04551547 | R, DB, PC vaccine study | 3–17y (n=552) | Recruiting |
| 2 | 04456439 | EAP of HMSC for MIS-C | 2mo–17y (n=~50) | Available |
| 3 | 04649151 | PC mRNA-1273 Vaccine S, RG, E study | 12–17y (n=3,000; 7 ctrs) | Not yet recruiting |
| 4 | 04431453 | S, T, PK, E of remdesivir | <17y (n=52; 30 ctrs) | Recruiting |
| 5 | 04646031 | Open label EAP of T89 botanical drug | C+A+OA | Available |
| 6 | 04368728 | R, PC, BNT162b1 + BNT162b2 | >12y (n=43,998; 155 ctrs) | Recruiting |
| 7 | 04362137 | R, DB, PC ruxolitinib in CS | >12y (n=432; 61 ctrs) | Completed |
| 8 | 04409262 | R+T versus R+P in severe pneumonia | >12y (n=500; 73 ctrs) | Recruiting |
| 9 | 04597047 | MC diagnostic study | C+A+OA (n=200) | Recruiting |
| 10 | 04355793 | EAP ruxolitinib in CS | >12y | Recruiting |
| 11 | 04377620 | PC ruxolitinib in ventilated ARDS pts | >12y (n=500; 35 ctrs) | Recruiting |
| 12 | 04362189 | PC study of HB-adMSCs | C+A+OA (n=100) | Active non-recruiting |
| 13 | 04486313 | PC, S, E of nitazoxanide | >12y (n=800) | Recruiting |
| 14 | 04427501 | PC, R, LY-CoV555 + LY-CoV016 | >12y (n=1,200) | Recruiting |
| 15 | 04292899 | S, E of remdesivir in severe COVID-19 | >12y (n=4,891; 183 ctrs) | Completed |
| 16 | 04501952 | S, E of remdesivir in outpatients | >12y (n=1,264; 45 ctrs) | Recruiting |
| 17 | 04377711 | R, DB, PC ciclesonide in outpatients | 12–100y (n=400) | Recruiting |
| 18 | 04348435 | R, DB, PC, S, E, HB-adMSCs to protect against COVID-19 | C+A+OA (n=100) | Enrolling by invitation |
| 19 | 04292730 | Remdesivir vs. SoC | >12y (n=1,113; 184 pts) | Completed |
| 20 | 04337359 | Ruxolitinib MAP | 6–90y | Available |
| 21 | 04362813 | DB, PC, S, E canakinumab in pneumonia | >12y (n=451) | Active non-recruiting |
| 22 | 04422509 | Lanadelumab | >16y (n=80; 10 ctrs) | Recruiting |
| 23 | 04566770 | Vaccine study | >6y (n=481) | Recruiting |
| 24 | 04471519 | DB, PC, vaccine study | 12–65y (n=755) | Recruiting |
| 25 | 04617535 | Compassionate use REGN-COV2 | C+A+OA | Available |
| 26 | 04603651 | Bamlanivimab EAP | >12y | No longer available |
| 27 | 04349631 | HB-adMSCs to protect against COVID-19 | C+A+OA (n=56) | Active non-recruiting |
| 28 | 04323761 | EAP remdesivir | >12y | Approved for marketing |
| 29 | 04360096 | Inhaled aviptadil | 12–85y (n=288) | Not yet recruiting |
| 30 | 04453839 | Aviptadil EAP | 12–100y (n=24) | Available |
| 31 | 03808922 | PC, DAS181 (1 subgroup only) | C+A+OA (n=274; 58 ctrs) | Recruiting |
| 32 | 04452318 | PC, REGN10933+REGN10987 protection | >12y (n=2,000) | Recruiting |
| 33 | 04579640 | Open-label randomized vitamin D to reduce risk and severity of COVID-19 | >16y (n=6,200) | Active non-recruiting |
ARDS, acute respiratory distress syndrome; C+A+OA, child+adult+older adult; CS, cytokine storm; DB, double-blind; E, efficacy; EAP, expanded access program; HB-adMSCs, Hope Biosciences allogeneic adipose-derived mesenchymal stem cells; HMSC, human mesenchymal stromal cells; MAP, managed access program; MC, multicenter; MIS-C, multisystem inflammatory syndrome in children; mo, months; PC, placebo-controlled; PK, pharmacokinetics; R, remdesivir; R+P, remdesivir+placebo; R+T, remdesivir+tocilizumab; RG, reactogenicity; S, safety; SoC, standard of care; T, tolerability; y, years.